Evaluating the Outcomes of Balloon Sinuplasty in Patients With Chronic Rhinosinusitis: A Systematic Review

Abstract

Moamen Abdelfadil Ismail*, DuaaFaleh Alshammari, Abdulrahman Abdullah S Alelyani, Yasmeen Saleem E Alhawiti, Nawaf Ahmad Almutairi, Muzun Saeed O Al Rathwan, Hassan Mansour ALBarakati, Israa Ali Dahach, Fatimah Abduljalil Altayeb, Abdulrahman Khaled Alshuaib

Background: Chronic rhinosinusitis (CRS) significantly impairs patient quality of life, and while functional endoscopic sinus surgery (FESS) is a standard intervention, balloon sinuplasty (BSP) has emerged as a minimally invasive alternative.

Objective: To systematically review the outcomes of BSP in CRS patients, assessing its effectiveness, safety, and long-term durability in comparison to conventional surgical options.

Methods: Following PRISMA 2020 guidelines, a systematic review was conducted across PubMed, Scopus, Web of Science, Embase, and Cochrane Library databases. Eligible studies included randomized controlled trials, cohort studies, and systematic reviews from 2010 to 2025. Data extraction focused on patient characteristics, intervention details, outcomes (SNOT scores, radiological/endoscopic findings, complications, revision surgery, and quality of life), and follow-up duration. Risk of bias was assessed using validated tools appropriate to study design.

Results: Ten studies met the inclusion criteria. BSP consistently improved sinonasal symptoms, radiological scores, and patient-reported quality of life, with complication rates lower than those reported for FESS. Long- term follow-up studies demonstrated sustained benefits, and Pediatric studies confirmed efficacy and safety in younger populations. Comparisons with FESS indicated that while BSP offers faster recovery and fewer complications, FESS may remain superior in more extensive disease.

Conclusion: BSP is a safe and effective treatment for selected CRS patients, providing durable symptom relief and high patient satisfaction. However, careful patient selection is essential, and additional high-quality trials are required to further define its role in CRS management.